Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
CC transcript

MAXCYTE, INC. (MXCT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
07/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/12/2023 4 Doerfler Douglas (President and CEO) has filed a Form 4 on MAXCYTE, INC.
Txns: Sold 445 shares @ $5.01, valued at $2.2k
Sold 12,798 shares @ $5.04, valued at $64.5k
Sold 16,757 shares @ $5.02, valued at $84.1k
Exercised 445 options to buy @ $0.04, valued at $17.8
Exercised 12,798 options to buy @ $0.04, valued at $511.9
Exercised 16,757 options to buy @ $0.04, valued at $670.3
07/10/2023 144 Form 144 - Report of proposed sale of securities:
06/28/2023 4 Johnston John Joseph (Director) has filed a Form 4 on MAXCYTE, INC.
Txns: Sold 7,529 shares @ $4.49, valued at $33.8k
Sold 7,471 shares @ $4.39, valued at $32.8k
Exercised 6,817 options to buy @ $0.983, valued at $6.7k
Exercised 712 options to buy @ $1.641, valued at $1.2k
Exercised 7,471 options to buy @ $1.641, valued at $12.3k
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
05/05/2023 4 Doerfler Douglas (President and CEO) has filed a Form 4 on MAXCYTE, INC.
Txns: Sold 16,149 shares @ $5.02, valued at $81.1k
Exercised 16,149 options to buy @ $0.04, valued at $646
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/04/2023 4 Ross Thomas M. (EVP, Global Sales & Marketing) has filed a Form 4 on MAXCYTE, INC.
Txns: Sold 2,607 shares @ $5, valued at $13k
Sold 100 shares @ $5.01, valued at $501
Sold 7,266 shares @ $5.03, valued at $36.5k
Exercised 2,607 options to buy @ $2.142, valued at $5.6k
Exercised 100 options to buy @ $2.142, valued at $214.2
Exercised 7,266 options to buy @ $2.142, valued at $15.6k
04/04/2023 4 Doerfler Douglas (President and CEO) has filed a Form 4 on MAXCYTE, INC.
Txns: Sold 2,607 shares @ $5, valued at $13k
Sold 100 shares @ $5.01, valued at $501
Sold 7,470 shares @ $5.03, valued at $37.6k
Exercised 2,607 options to buy @ $0.04, valued at $104.3
Exercised 100 options to buy @ $0.04, valued at $4
Exercised 7,470 options to buy @ $0.04, valued at $298.8
03/30/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/28/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
03/28/2023 8-K Quarterly results
03/21/2023 4 Holtz Ron (CFO) has filed a Form 4 on MAXCYTE, INC.
Txns: Granted 120,000 options to buy @ $4.19, valued at $502.8k
03/21/2023 4 Hemrajani Rekha (Director) has filed a Form 4 on MAXCYTE, INC.
Txns: Granted 40,000 options to buy @ $4.19, valued at $167.6k
03/21/2023 4 Al-Wakeel Yasir B. (Director) has filed a Form 4 on MAXCYTE, INC.
Txns: Granted 40,000 options to buy @ $4.19, valued at $167.6k
03/21/2023 4 Masoud Maher (EVP and General Counsel) has filed a Form 4 on MAXCYTE, INC.
Txns: Granted 120,000 options to buy @ $4.19, valued at $502.8k
03/21/2023 4 Ross Thomas M. (EVP, Global Sales & Marketing) has filed a Form 4 on MAXCYTE, INC.
Txns: Granted 120,000 options to buy @ $4.19, valued at $502.8k
03/21/2023 4 Doerfler Douglas (President and CEO) has filed a Form 4 on MAXCYTE, INC.
Txns: Granted 400,000 options to buy @ $4.19, valued at $1.7M
03/21/2023 4 Sumen Cenk (Chief Scientific Officer) has filed a Form 4 on MAXCYTE, INC.
Txns: Granted 500,000 options to buy @ $5.7, valued at $2.9M
Granted 120,000 options to buy @ $4.19, valued at $502.8k
03/15/2023 10-K Annual Report for the period ended December 31, 2022
03/15/2023 8-K Quarterly results
03/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/31/2023 SC 13G/A BlackRock Inc. reports a 7.6% stake in MAXCYTE, INC.
01/10/2023 SC 13G/A Casdin Capital, LLC reports a 9% stake in MaxCyte, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy